| 摘要: |
| ［摘要］ 目的 探讨烯丙雌醇治疗育龄期排卵障碍性异常子宫出血的临床疗效及安全性。方法 回顾性分析2023年1月至2024年11月南京医科大学第三附属医院（常州市第二人民医院）妇科收治的207例育龄期排卵障碍性异常子宫出血患者的临床资料，按照治疗方法分为观察组90例和对照组117例。观察组于月经第15天开始口服烯丙雌醇5 mg，2次/d，持续口服给药14 d为1个疗程；对照组于月经第15天开始口服地屈孕酮10 mg，2次/d，持续口服给药14 d为1个疗程。两组均连续用药3个疗程。比较两组治疗前后月经量［采用月经失血图（PBAC）评分进行评估］、子宫内膜厚度和血红蛋白水平；比较两组临床疗效、症状缓解时间、症状消失时间及不良反应发生率。结果 观察组和对照组的临床总有效率分别为93.33%和91.45%，两组比较差异无统计学意义（P>0.05）。治疗后，两组PBAC评分及子宫内膜厚度较治疗前显著下降（P<0.05），而血红蛋白水平较治疗前显著升高（P<0.05），但组间比较差异无统计学意义（P>0.05）。观察组症状缓解时间和症状消失时间快于对照组，差异有统计学意义（P<0.05）。观察组的不良反应发生率为8.89%（8/90），对照组的不良反应发生率为5.13%（6/117），两组比较差异无统计学意义（P>0.05）。结论 烯丙雌醇在治疗育龄期排卵障碍性异常子宫出血与地屈孕酮有相似的疗效，且在短疗程临床用药有较好的安全性。 |
| 关键词: 烯丙雌醇 地屈孕酮 育龄期 排卵障碍性异常子宫出血 |
| DOI：10.3969/j.issn.1674-3806.2025.05.08 |
| 分类号: |
| 基金项目:中国医药卫生事业发展基金会医药科研课题项目（编号：BJ2023YCPYJH003）；江苏省妇幼健康重点人才项目（编号：RC202101）；江苏省妇幼健康科研项目（编号：F202138）；常州市卫生健康人才国外研修资助项目（编号：GW2023024）；常州市“十四五”卫生健康高层次人才培养工程（编号：2022CZBJ074）；常州市卫健委科技项目重大项目（编号：ZD202314） |
|
| Clinical efficacy and safety of allylestrenol in treatment of abnormal uterine bleeding due to ovulatory dysfunction in childbearing age |
|
JIA Qiucheng, WEI Weiwei, CHEN Jiming, YU Yi, CHEN Wanying, LIU Chi, CAO Ying, XUE Wenpeng, XING Tingwei, LIU Junling, MIN Yifei
|
|
Department of Gynecology, the Third Affiliated Hospital of Nanjing Medical University(Changzhou No.2 People′s Hospital), Changzhou 213000, China
|
| Abstract: |
| ［Abstract］ Objective To explore the clinical efficacy and safety of allylestrenol in treatment of abnormal uterine bleeding due to ovulatory dysfunction in childbearing age. Methods The clinical data of 207 patients with abnormal uterine bleeding due to ovulatory dysfunction in childbearing age who were admitted to Department of Gynecology, the Third Affiliated Hospital of Nanjing Medical University(Changzhou No.2 People′s Hospital) from January 2023 to November 2024 were retrospectively analyzed. The patients were divided into observation group(90 cases) and control group(117 cases) according to different treatment methods. The observation group began to take 5 mg of allylestrenol orally on the 15th day of menstruation, twice a day, and continued oral administration for 14 days as 1 course of the treatment. The control group began to take 10 mg of dydrogesterone orally on the 15th day of menstruation, twice a day, and continued oral administration for 14 days as one course of the treatment. Both groups were treated with medication for three consecutive courses. The menstrual volume［Pictorial Blood Loss Assessment Chart(PBAC) score was used for assessment］, endometrial thickness and hemoglobin level were compared between the two groups before and after treatment. The clinical efficacy, symptom relief time, symptom disappearance time and incidence of adverse reactions were compared between the two groups. Results The total clinical effective rate was 93.33% in the observation group and 91.45% in the control group. There was no statistically significant difference in the total clinical effective rate between the two groups(P>0.05). After the treatments, the PBAC scores and endometrial thickness in both groups decreased significantly compared with those before the treatments(P<0.05), and the hemoglobin levels in both groups increased significantly compared with those before the treatments(P<0.05), but there were no statistically significant differences between the two groups(P>0.05). The symptom relief time and symptom disappearance time in the observation group was faster than that in the control group, with statistically significant difference between the two groups(P<0.05). The incidence of adverse reactions in the observation group was 8.89%(8/90), and that in the control group was 5.13%(6/117). There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion Allylestrenol and dydrogesterone have similar efficacy in treatment of abnormal uterine bleeding due to ovulatory dysfunction in childbearing age, and both have good safety in short-course clinical medications. |
| Key words: Allylestrenol Dydrogesterone Childbearing age Abnormal uterine bleeding due to ovulatory dysfunction |
